Neurology · PTSDTrial Updateclinicalmid-term

Intranasal Insulin Shows Potential for Treating PTSD Symptoms

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 12:30:59 PM

Assessment confidence: 57% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of intranasal insulin for PTSD could introduce a novel treatment option, potentially reshaping the therapeutic landscape for PTSD. Success in this trial may compel portfolio teams to reassess their strategies regarding PTSD therapies and consider integration of this new approach. Regulatory context from FDA (Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment) supports the near-term read. Assessment grounded in 17 ranked evidence items (4 high-relevance).

Strategic Assessment

The strongest clinical anchor is Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial (ClinicalTrials.gov), mechanism alignment (io ). In Neurology · PTSD, 3 regulatory and 2 competitive items passed relevance filtering for PTSD treatment market. If intranasal insulin proves effective, it could capture market share from existing PTSD treatments, influencing revenue streams for companies involved in this therapeutic area.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation. If successful, this could position intranasal insulin as a novel treatment option in the PTSD market, impacting current therapies.

Regulatory Outlook

Regulatory risk is concentrated around Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment (FDA). Moderate corpus alignment. Successful trial outcomes could lead to expedited regulatory pathways for approval, impacting compliance and labeling for PTSD treatments.

Key Risks

Elevated medium regulatory exposure for PTSD treatment market could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial) could weigh on PTSD treatment market through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If intranasal insulin proves effective, it could capture market share from existing PTSD treatments, influencing revenue streams for companies involved in this therapeutic area.
The potential integration of intranasal insulin into PTSD treatment strategies if results are favorable.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety data.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of COVID-19 Treatment Authorized for Emergency Use
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing - 09/14/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Intranasal Insulin for Posttraumatic Stress Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: Randomized Control Trial.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Palbociclib (PD-0332991) as Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PTSD treatment market

Commercial impact

medium

If intranasal insulin proves effective, it could capture market share from existing PTSD treatments, influencing revenue streams for companies involved in this therapeutic area.

Regulatory impact

medium

Successful trial outcomes could lead to expedited regulatory pathways for approval, impacting compliance and labeling for PTSD treatments.

What to watch

Monitor trial results and any announcements regarding efficacy and safety data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.